Detalhe da pesquisa
1.
FDA Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development.
Clin Infect Dis
; 2023 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37802928
2.
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
Mov Disord
; 31(9): 1373-80, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27214664
3.
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Brain
; 138(Pt 4): 963-73, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25669730
4.
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Mov Disord
; 29(8): 1074-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24865335
5.
Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches.
Expert Rev Neurother
; 20(10): 1047-1064, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758042
6.
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Neuropharmacology
; 167: 108006, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32086070
7.
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Neuropharmacology
; 170: 108024, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32142791
8.
Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo.
Exp Neurol
; 328: 113287, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32205118
9.
Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
Pain Med
; 10(4): 633-8, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19453958
10.
Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
J Parkinsons Dis
; 7(4): 629-634, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28777756
11.
Metabotropic glutamate receptor 5: a target for migraine therapy.
Ann Clin Transl Neurol
; 3(8): 560-71, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27606340
12.
Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe.
Curr Med Res Opin
; 20(9): 1465-72, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15383196
13.
Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation.
BJU Int
; 99(2): 369-75, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17129234
14.
Dose range-finding studies with frovatriptan in the acute treatment of migraine.
Headache
; 42 Suppl 2: S74-83, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12028323
15.
Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Headache
; 42 Suppl 2: S93-9, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12028325
16.
Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.
Headache
; 43(4): 376-88, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12656709
17.
Frovatriptan use in migraineurs with or at high risk of coronary artery disease.
Headache
; 44(5): 403-10, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15147247
18.
Consequences of transforming measures of efficacy for acute therapies: 5-HT agonists as a worked example.
Headache
; 44(1): 48-52, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14979883
19.
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Neurology
; 63(2): 261-9, 2004 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-15277618
20.
Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT(1B/1D) agonist efficacy in migraine.
Headache
; 42(7): 680-8, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12482223